Experts highlight key data to help you learn what to expect at the upcoming Hematology meeting in Atlanta. The CCO ASH Conference Coverage program will feature downloadable slides and expert analysis of these and dozens of other clinically relevant studies presented at ASH. We will have the information you need to understand and integrate the latest hematology data into your practice.
In this pooled analysis, median PFS was nearly 4 years and duration of response was nearly 4.5 years for those patients with relapsed/refractory MCL who achieved a CR with single agent ibrutinib therapy.
After a median follow-up of nearly 5 years, initial treatment with lenalidomide plus rituximab achieved a CR rate of 61%, with many patients in CR achieving MRD negativity.
In patients with R/R MCL, acalabrutinib monotherapy was associated with an ORR of 81% and ongoing responses at 12 months in 72% of these patients.
High patient baseline levels of tumor burden, LDH, and inflammatory biomarkers were associated with high levels of CAR T-cell expansion but increased rates of CRS and neurotoxicity.
The addition of polatuzumab vedotin to BR significantly increased ORR and CR rates in transplantation-ineligible patients with relapsed/refractory DLBCL vs BR alone.
A CR was achieved in 100% of patients with R/R HCL treated with the chemotherapy-free combination of vemurafenib plus rituximab.
Ibrutinib plus venetoclax for 6 months achieved deep responses with 1 in 3 patients attaining minimal residual disease–negative bone marrow.
In this interim analysis, venetoclax plus ibrutinib combination therapy achieved high response rates in patients with CLL, with many patients achieving MRD-negative bone marrow.
In patients with FL treated with BR induction therapy, 4 years vs 2 years of rituximab maintenance appears to improve PFS.
Tisagenlecleucel (CTL019) demonstrated an ORR of 53% with most CRs sustained at 6 months in patients with hard-to-treat relapsed/refractory DLBCL.
The chemotherapy-free combination of brentuximab vedotin plus nivolumab achieved a CR of 62% as first salvage therapy in patients with relapsed/refractory classical Hodgkin lymphoma without adverse effects on subsequent transplantation.
In patients with R/R cHL who continued nivolumab treatment following progression, 53% experienced reductions in tumor burden.
Brentuximab vedotin plus AVD reduced the risk of progression, death, or need for further anticancer therapy by 23% vs standard ABVD in patients with previously untreated advanced classical Hodgkin lymphoma.
In this expert analysis, John M. Burke, MD, and Christopher R. Flowers, MD, review and provide their perspective on key lymphomas and CLL studies presented at the Hematology 2017 annual meeting.
In a preplanned interim analysis of this phase III study, venetoclax plus rituximab significantly improved median PFS independent of del(17p) status vs bendamustine plus rituximab, with 60% of patients maintaining MRD negativity at 18 months.
Review promising preliminary findings from a phase I/II trial assessing combination therapy with inotuzumab ozogamicin and bosutinib in patients with relapsed/refractory Philadelphia chromosome–positive ALL or CML in lymphoid blast phase.
No clear evidence of benefit associated with midostaurin maintenance therapy in this unplanned post hoc subset analysis of the RATIFY trial.
Observational study found that a TKI duration of 5.8 years and MR4 duration of 3.1 years decreased the likelihood of relapse for patients with CML discontinuing TKI therapy.
Azacitidine was well tolerated and significantly improved disease-free survival in older patients with anemia-refractory AML.
Results confirm strong prognostic value of NPM1/FLT3-ITD genotypes in AML, supporting 2017 ELN risk stratification criteria that include FLT3-ITD allelic burden.
Preliminary data suggest novel combination of gilteritinib and chemotherapy has antileukemic effect in FLT3-mutated AML with acceptable safety.
Ivosidenib, an investigational mutant IDH1 inhibitor, was well tolerated with evidence of activity and durable responses in patients with malignancies harboring mutated IDH1.
The combination of IDH inhibitors enasidenib or ivosidenib with standard 7 + 3 induction chemotherapy appears safe with response rates comparable to those expected with standard induction chemotherapy in patients with either de novo or secondary AML.
Study reported median event-free survival of 8.3 months in patients receiving nivolumab plus cytarabine and idarubicin with manageable safety profile.
After more than 1 year of follow-up, the combination of venetoclax plus low-dose cytarabine achieved a CR + CRi rate of 62% and a median OS of 11.4 months in elderly patients with AML who are unfit for chemotherapy.
Preliminary findings demonstrate that the CPX-351 liposomal formulation of cytarabine:daunorubicin is both safe and active at reduced and higher doses in patients with AML at high risk for death during induction chemotherapy.
Combining peginterferon-alfa 2a with nilotinib in patients with chronic-phase CML showed significantly better rates of deep molecular response than nilotinib alone.
Ponatinib combined with steroids yielded a 90% complete hematologic response and reasonable tolerability profile at Week 24 in unfit and elderly patients with Philadelphia chromosome–positive ALL.
In this expert analysis, Farhad Ravandi, MD, and B. Douglas Smith, MD, review the clinically relevant studies on the management of acute and chronic leukemias presented at the Hematology 2017 annual meeting.
This large prospective study shows that identification of residual leukemia by targeted next-generation sequencing of select mutations present in CR serves as a strong independent predictor for AML relapse and survival.
This prospective subanalysis of the phase III EMN02/HO95 trial suggests benefit in PFS and OS with double ASCT, particularly for patients with high-risk MM.
The use of KRd induction plus transplantation and consolidation resulted in a CR or better in approximately 75% of patients with high-risk smoldering myeloma with an acceptable safety profile.
BCMA-CART with or without cyclophosphamide lymphodepletion demonstrates promising clinical activity in heavily pretreated patients with MM.
Combined infusion of CD19- and BCMA-specific CAR T-cells generally well tolerated and produces high remission rates in patients with relapsed/refractory multiple myeloma.
Daratumumab monotherapy demonstrated clinical activity and a favorable safety profile in patients with intermediate- and high-risk smoldering multiple myeloma.
Extended follow-up continues to demonstrate significant increase in PFS with addition of daratumumab to lenalidomide/dexamethasone for patients with relapsed/refractory myeloma.
Results from the dose escalation show that second-generation bb2121 CAR T-cell therapy yielded a 94% ORR and a 56% CR rate in heavily pretreated patients with relapsed/refractory MM.
A new human scFv-derived BCMA-targeted CAR T-cell appears tolerable with no reported dose-limiting toxicity and preliminary evidence of activity in patients with heavily pretreated myeloma.
In evaluable patients who relapsed following initial RVD therapy (with or without upfront ASCT), 4 cycles of PCD yielded an ORR of 85% with 95% of transplant-naive patients proceeding to a first ASCT.
The use of manual subcutaneous injection of coformulation of daratumumab and rHuPH20 enabled short administration, was well tolerated, and demonstrated a response rate similar to IV daratumumab.
Use of elotuzumab/lenalidomide/dexamethasone maintenance therapy following autologous stem cell transplantation in patients with multiple myeloma improved quality of response in 36% of patients in this preliminary analysis.
Among patients with newly diagnosed MM not undergoing ASCT, ixazomib-based induction followed by ixazomib maintenance therapy was associated with an ORR of 94%, including a CR rate of 35%.
In this online course, Shaji Kumar, MD, and Sagar Lonial, MD, discuss the results and provide their perspective on the clinical applicability of key multiple myeloma studies presented at the Hematology 2017 annual meeting.
The combination of daratumumab plus VMP reduced the risk of progression or death by 50% vs VMP alone in transplantation-ineligible patients with newly diagnosed myeloma in this randomized, open-label phase III study.
Most treatment-emergent adverse events were mild to moderate in adult ITP patients receiving 4 or 7 mg/kg of rozanolixizumab subcutaneously.
Cumulative duration of platelet response ≥ 50 x 109/L without rescue therapy was superior with avatrombopag vs placebo.
At full cost, rivaroxaban increases total healthcare costs but lowers clinical event costs vs aspirin when given as extended anticoagulant therapy for VTE.
In this post hoc analysis, platelet counts ≥ 50 x 109/L were reached without rescue therapy in 84% of patients with persistent ITP vs 88% with chronic ITP.
In this subgroup analysis of a phase II study, high-dose crizanlizumab delayed sickle cell–related pain crises across all defined subgroups of patients with sickle cell disease.
Compared with dalteparin, rivaroxaban was associated with a lower incidence of VTE recurrence within 6 months but a higher incidence of clinically relevant bleeding events.
Initiation of eltrombopag reduced mean number of transfusions and healthcare resource utilization rates vs before eltrombopag administration.
Emicizumab prevented or reduced bleeding episodes requiring treatment and was well tolerated by this pediatric population.
Preliminary analysis finds that pharmacokinetic parameters of SC emicizumab Q4W were promising and consistent with previous observations.
In this Expert Analysis of key data from the Hematology 2017 annual meeting, Julie Kanter, MD; Gary Lyman, MD, MPH, FASCO, FRCP (Edin); Keith R. McCrae, MD; and Guy A. Young, MD, discuss the clinical applicability of new findings in nonmalignant hematologic disorders presented at the conference, including sickle cell disease, immune thrombocytopenia, hemophilia A, venous thromboembolism, and aplastic anemia.
Oral edoxaban was noninferior to subcutaneous dalteparin regarding combined risk of recurrent VTE or major bleeding in patients with cancer-associated VTE.
At a median follow-up of 33.9 months, brentuximab vedotin showed superior outcomes and durable responses vs either methotrexate or bexarotene for patients with previously treated, CD30-positive mycosis fungoides or primary cutaneous anaplastic large-cell lymphoma.
Avapritinib was well tolerated and safe across several dose levels with an ORR of 72% by IWG-MRT-ECNM criteria.
Novel chemotherapy-free combination of avadomide plus obinutuzumab tolerable and active in patients with relapsed/refractory NHL.
The combination of acalabrutinib and obinutuzumab yielded ORR rates exceeding 90% that deepened over time, along with a favorable safety profile.
Mogamulizumab approximately doubled median PFS compared with vorinostat in patients with previously treated CTCL.
In this expert analysis of key data from the Hematology 2017 annual meeting, the clinical implications of new targeted therapeutic strategies in multiple hematologic diseases (NHL, CLL, CTCL, systemic mastocytosis, and acquired TTP) are reviewed by Farrukh Awan, MD, MS; Madeleine Duvic, MD; Daniel J. DeAngelo, MD, PhD; and Marie Ann Scully, MD.
Composite of aTTP-related death, aTTP recurrence, and major thromboembolic events significantly reduced with caplacizumab vs placebo.
*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.